Please use this identifier to cite or link to this item:
|Title:||Testosterone is lower in men with non-alcoholic fatty liver disease and alcohol-related cirrhosis and is associated with adverse clinical outcomes.||Austin Authors:||Apostolov, Ross ;Wong, Darren;Low, Elizabeth S L ;Vaz, Karl;Spurio, Jessica;Worland, Thomas ;Liu, Dorothy ;Chan, Roseanne Kimberley;Gow, Paul J ;Grossmann, Mathis ;Sinclair, Marie||Affiliation:||Victorian Liver Transplant Unit
Gastroenterology and Hepatology
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
|Issue Date:||6-Jun-2023||Date:||2023||Publication information:||Scandinavian Journal of Gastroenterology 2023||Abstract:||Low serum testosterone is common in cirrhotic men, but the impact of disease aetiology remains uncertain. This study compares serum total testosterone (TT) levels by disease aetiology and assesses its prognostic value. Single-centre retrospective study of cirrhotic men who had TT levels measured between 2002 and 2020. A cut-off of 12 nmol/L was used to define low TT and 230 pmol/L for calculated free testosterone (cFT). Linear and logistic regression used to adjust for variables known to affect testosterone levels and assess for an association between levels and outcomes. Of 766 cirrhotic men, 33.3% had alcohol-related liver disease (ALD) and 11.9% had non-alcoholic fatty liver disease (NAFLD). The median age was 56 years (interquartile range (IQR) 50-61), and the model for end-stage liver disease (MELD) score 14 (IQR 9-20). TT levels were low in 53.3% of patients, (median 11.0 nmol/L; IQR 3.7-19.8) and cFT low in 79.6% (median 122 pmol/L; IQR 48.6-212). Median TT was lower in men with ALD (7.6 nmol/L; IQR 2.1-16.2) and NAFLD (9.8 nmol/L; IQR 2.75-15.6) compared to other aetiologies (11.0 nmol/L; IQR 3.73-19.8) (p < 0.001 for all), which remained true after adjustment for age and MELD score. TT was inversely associated with 12-month mortality or transplant (381 events, p = 0.02) and liver decompensation (345 events, p = 0.004). Low serum testosterone is common in cirrhotic men and is associated with adverse clinical outcomes. TT levels are significantly lower in ALD and NAFLD compared to other disease aetiologies. Further large-scale studies are required to assess the potential benefits of testosterone therapy.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/33078||DOI:||10.1080/00365521.2023.2220857||ORCID:||0000-0002-4827-8795
|Journal:||Scandinavian Journal of Gastroenterology||Start page:||1||End page:||7||PubMed URL:||37282344||ISSN:||1502-7708||Type:||Journal Article||Subjects:||Testosterone
alcohol-related liver disease
non-alcoholic fatty liver disease
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 3, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.